BIOMAT Database Logo BIOMAT Database Logo

Effect of octreotide on glucose tolerance in acromegaly. 1994

B L Koop, and A G Harris, and S Ezzat
Department of Medicine, Cedars-Sinai Medical Center, UCLA School of Medicine 90048.

To determine the effect of the somatostatin analog octreotide on glucose tolerance in acromegaly, we examined glucose profiles, oral glucose tolerance and the insulinogenic index in patients treated with this analog. Ninety patients participated in a long-term, prospective, open-label study. There was no significant change between mean daily blood glucose profiles at baseline or during octreotide treatment. Using glucose tolerance test criteria, 61% of 90 patients had normal baseline glucose tolerance. While on octreotide, 20% and 29% of these patients, respectively, developed impaired glucose tolerance or became frankly diabetic. Conversely, three of the patients who were diabetic at baseline (N = 11) became normal (18%) or developed impaired glucose tolerance (9%) during octreotide therapy. There was no relationship between the dose of octreotide and change in glycemic state. The insulinogenic index (insulin/glucose) response to a glucose challenge decreased uniformly in octreotide-treated patients. Female patients and those with elevated baseline insulin levels were more likely to develop diabetes mellitus during octreotide therapy. In conclusion, octreotide significantly alters glucose tolerance in patients with acromegaly, mandating glucose monitoring during this form of therapy.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008297 Male Males
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D002940 Circadian Rhythm The regular recurrence, in cycles of about 24 hours, of biological processes or activities, such as sensitivity to drugs or environmental and physiological stimuli. Diurnal Rhythm,Nyctohemeral Rhythm,Twenty-Four Hour Rhythm,Nycthemeral Rhythm,Circadian Rhythms,Diurnal Rhythms,Nycthemeral Rhythms,Nyctohemeral Rhythms,Rhythm, Circadian,Rhythm, Diurnal,Rhythm, Nycthemeral,Rhythm, Nyctohemeral,Rhythm, Twenty-Four Hour,Rhythms, Circadian,Rhythms, Diurnal,Rhythms, Nycthemeral,Rhythms, Nyctohemeral,Rhythms, Twenty-Four Hour,Twenty Four Hour Rhythm,Twenty-Four Hour Rhythms
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D005260 Female Females
D005951 Glucose Tolerance Test A test to determine the ability of an individual to maintain HOMEOSTASIS of BLOOD GLUCOSE. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg). Intravenous Glucose Tolerance,Intravenous Glucose Tolerance Test,OGTT,Oral Glucose Tolerance,Oral Glucose Tolerance Test,Glucose Tolerance Tests,Glucose Tolerance, Oral
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000078790 Insulin Secretion Production and release of insulin from PANCREATIC BETA CELLS that primarily occurs in response to elevated BLOOD GLUCOSE levels. Secretion, Insulin

Related Publications

B L Koop, and A G Harris, and S Ezzat
Divergent effects of octreotide on glucose tolerance in patients with acromegaly.
May 1997, Internal medicine (Tokyo, Japan),
B L Koop, and A G Harris, and S Ezzat
Short-term effects of octreotide on glucose tolerance in patients with acromegaly.
December 1995, Endocrine journal,
B L Koop, and A G Harris, and S Ezzat
[The effect of acromegaly treatment on glucose tolerance].
November 1986, Casopis lekaru ceskych,
B L Koop, and A G Harris, and S Ezzat
Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly.
March 1992, Clinical endocrinology,
B L Koop, and A G Harris, and S Ezzat
Effect of octreotide on plasma lipid metabolism in acromegaly.
October 1994, The Annals of pharmacotherapy,
B L Koop, and A G Harris, and S Ezzat
Effect of octreotide pretreatment on surgical outcome in acromegaly.
October 1997, The Journal of clinical endocrinology and metabolism,
B L Koop, and A G Harris, and S Ezzat
Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant.
December 2003, European journal of endocrinology,
B L Koop, and A G Harris, and S Ezzat
Long-term effect of octreotide in acromegaly on insulin resistance.
May 1995, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
B L Koop, and A G Harris, and S Ezzat
Changes in glucose tolerance and development of gall stones during high dose treatment with octreotide for acromegaly.
September 1989, BMJ (Clinical research ed.),
B L Koop, and A G Harris, and S Ezzat
[Studies on disorders in the glucose tolerance during acromegaly].
March 1974, Endokrinologie,
Copied contents to your clipboard!